pharma · Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy (DMD) · TRDA
Entrada Therapeutics
Entrada Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker TRDA. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD). Nov
Boston, USA HQ
2016 Founded
201 Employees
Public company Type
TRDA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2016
- Employees
- 201
- Programs
- 4
- Drugs
- 4
- Patents
- 5
ENTR-601-45
Phase 2 · small molecule · Duchenne Muscular Dystrophy (DMD)
ENTR-601-45 for Duchenne Muscular Dystrophy (DMD) is a Phase 2 program (small_molecule) at Entrada Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ENTR-601-45-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Entrada Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Duchenne Muscular Dystrophy (DMD)
- Status
- active
- Trials
- 1